TD Cowen Issues Pessimistic Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its price target lowered by TD Cowen from $160.00 to $153.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company's stock.

A number of other equities research analysts have also recently weighed in on ASND. Bank of America lifted their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a report on Monday, September 23rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. Stifel Nicolaus increased their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research note on Friday. Wedbush restated an "outperform" rating and set a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday. Finally, The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $191.77.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND traded up $2.23 during trading on Friday, reaching $126.51. 1,448,861 shares of the company's stock traded hands, compared to its average volume of 450,130. The stock has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The company has a 50 day moving average of $132.30 and a 200-day moving average of $132.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. Equities research analysts predict that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of ASND. Signaturefd LLC boosted its holdings in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after buying an additional 80 shares during the period. Profund Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock valued at $398,000 after acquiring an additional 85 shares in the last quarter. Rhumbline Advisers boosted its stake in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after purchasing an additional 143 shares during the period. Thrivent Financial for Lutherans grew its position in Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock worth $11,717,000 after purchasing an additional 228 shares in the last quarter. Finally, Avior Wealth Management LLC raised its stake in Ascendis Pharma A/S by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company's stock valued at $1,226,000 after purchasing an additional 240 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.